In NASH patients, the lack of CYP7A1 repression, together with the increased levels of C4 in serum, suggests that there is no appropriate activation of the intestinal FXR/FGF19 axis, perhaps due to an insufficient level of BAs in intestinal cells. This evidence concerns the gene FGF19 and metabolic dysfunction-associated steatohepatitis.